UPDATE: Barclays Starts CONMED (CNMD) at Overweight

Barclays initiates coverage on CONMED (NASDAQ: CNMD) with a Overweight rating and a price target of $175.00.

The analyst comments "Our bullish view on CNMD comes down to two products – Buffalo Filter and AirSeal – that make up just over 25% of total sales. We estimate these two products alone can drive total company sales to at least high single digits and expand margins 60-80bps per year. CNMD is also attractive on a SOTP analysis valuing these two growth drivers separately."

For an analyst ratings summary and ratings history on CONMED click here. For more ratings news on CONMED click here.

Shares of CONMED closed at $101.41 yesterday.

You May Also Be Interested In

• DA Davidson Starts Everus (ECG) at Buy
• Keefe, Bruyette & Woods Resumes Canadian Imperial Bank of Commerce (CM:CN) (CM) at Market Perform
• Deere (DE) PT Raised to $585 at JPMorgan